Tesamorelin is a stabilized full-length GHRH(144) analog with a current FDA approval (Egrifta) and multiple Phase 3 trials
peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
J., Diamond A
Dietary PUFAs are widely present in oily fish, nuts, green leafy vegetables, soybeans, seeds, and grains
Chem Cent J
In Arabidopsis , there is a single gene encoding for GS, whereas, the soybean genome contains two GS and two hGS genes, with each pair sharing 87 and 93% identity, respectively